Eligibility for treatment with PCSK9 inhibitors among patients with stable coronary artery disease presumed to be on maximum hypolipidaemic therapy
Open Access
- 1 September 2018
- journal article
- letter
- Published by Elsevier in Hellenic Journal of Cardiology
- Vol. 59 (5) , 293-295
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Characteristics and Long-Term Prognosis of Patients ≤35 Years of Age with ST Segment Elevation Myocardial Infarction and “Normal or Near Normal” Coronary ArteriesThe American Journal of Cardiology, 2017
- Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid AssociationJournal of Clinical Lipidology, 2017
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseNew England Journal of Medicine, 2017
- Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGEREuropean Heart Journal - Cardiovascular Pharmacotherapy, 2016
- Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapyLipids in Health and Disease, 2016
- Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsHormones, 2016
- National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2Journal of Clinical Lipidology, 2015
- Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: A study of a cohort of 14,000 mutation carriersAtherosclerosis, 2014
- Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis SocietyEuropean Heart Journal, 2013
- Lipoprotein-Associated Phospholipase A2 Bound on High-Density Lipoprotein Is Associated With Lower Risk for Cardiac Death in Stable Coronary Artery Disease PatientsJACC, 2012